Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 212 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RSV Infections Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

NCT05127434
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, mRNA-1345
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
60 Years and older
Enrollment
36,814 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
133
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 11:42 PM EDT
Not yet recruiting Phase 4 Interventional

The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation

NCT07824167
View directory record Official record
Conditions
RSV Infection
Interventions
Clesrovimab
Biological
Lead sponsor
Emory University
Other
Eligibility
Up to 8 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 11:42 PM EDT
Completed Phase 3 Interventional Results available

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

NCT00129766
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
motavizumab (MEDI-524), palivizumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
Up to 24 Months
Enrollment
6,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
120
States / cities
Birmingham, Alabama • Pike Road, Alabama • Phoenix, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 22, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

NCT03473002
View directory record Official record
Conditions
Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
Interventions
Placebo, SeVRSV Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 22, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine

NCT01290419
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV-F Particle Vaccine, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 22, 2026, 11:42 PM EDT
Completed Phase 3 Interventional

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

NCT00014391
View directory record Official record
Conditions
Cancer
Interventions
palivizumab, ribavirin
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 22, 2026, 11:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

NCT06374394
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
841 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
8
States / cities
Coral Gables, Florida • Savannah, Georgia • Evansville, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 22, 2026, 11:42 PM EDT
Not yet recruiting Not applicable Interventional

Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings

NCT07217639
View directory record Official record
Conditions
COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus, RSV, Rhinovirus
Interventions
Aptitude Medical Systems Respiratory Panel Test
Diagnostic Test
Lead sponsor
Aptitude Medical Systems
Industry
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Trussville, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 22, 2026, 11:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

NCT02325791
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Suptavumab 30 mg/kg, Placebo Matched to Suptavumab, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Up to 6 Months
Enrollment
1,177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
107
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 104 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 22, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT01852266
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV cps2 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 22, 2026, 11:42 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

NCT03959488
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MEDI8897, Palivizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 1 Year
Enrollment
925 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
30
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 11:42 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

NCT03572062
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
Formulation A, Formulation B, Formulation C, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
South Miami, Florida • Peoria, Illinois • Fremont, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Oct 22, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

NCT06097299
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 22, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-323 in Healthy Subjects

NCT05587478
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-323, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 22, 2026, 11:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)

NCT05765396
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Virus, COVID-19 Pneumonia, Respiratory Infection, COVID-19 ARDS, Corona Virus Infection, Influenza, RSV Infection
Interventions
imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
Device
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 22, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults

NCT00192465
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MEDI-524 (Numax-TM)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2009 · Synced Oct 22, 2026, 11:42 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)

NCT06160128
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection, RSV, Influenza
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
400,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 11:42 PM EDT
Completed Phase 2 Interventional

Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

NCT01065935
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALN-RSV01, Normal Saline
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 22, 2026, 11:42 PM EDT
Recruiting Phase 3 Interventional

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

NCT05026749
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
AZM Group, Control Group
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
3 Days to 2 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 22, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus

NCT00496821
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALN-RSV01
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2007 · Synced Oct 22, 2026, 11:42 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

NCT04798001
View directory record Official record
Conditions
Covid19
Interventions
Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray
Biological
Lead sponsor
Meissa Vaccines, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Lenexa, Kansas • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 22, 2026, 11:42 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

NCT06102174
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Placebo, Active
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Day to 60 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 22, 2026, 11:42 PM EDT
Completed Not applicable Interventional

Music Therapy With Intubated and Sedated Pediatric Patients

NCT03629145
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Live Music Therapy, Recorded Music Therapy
Behavioral
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 2 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 22, 2026, 11:42 PM EDT
Terminated Phase 2 Interventional Results available

Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract

NCT04633187
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
16 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 22, 2026, 11:42 PM EDT